Merck Says Co's KEYTRUDAPlus Concurrent Chemoradiotherapy "Significantly Improved Progression-Free Survival" Vs oncurrent Chemoradiotherapy Alone In Newly Diagnosed, High-Risk Locally Advanced Cervical Cancer
Portfolio Pulse from Benzinga Newsdesk
Merck's KEYTRUDA plus concurrent chemoradiotherapy has shown significant improvement in progression-free survival in newly diagnosed, high-risk locally advanced cervical cancer patients. The treatment reduced the risk of disease progression or death by 30% compared to concurrent chemoradiotherapy alone. This is the first Phase 3 study where an immunotherapy regimen has demonstrated a significant PFS improvement in locally advanced cervical cancer.
October 20, 2023 | 2:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck's KEYTRUDA has shown significant improvement in progression-free survival in high-risk cervical cancer patients. This positive news could potentially boost Merck's stock in the short term.
The positive results from the Phase 3 study of KEYTRUDA, a product of Merck, could potentially increase the demand for the company's stock. Investors may see this as a sign of the company's strong product pipeline and potential for future growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100